MitoCareX Bio
Novel Therapies for Hard-to-treat Resistant Cancers
Startup Acquired Health Tech & Life Sciences Est. 2022
Total Raised
Undisclosed
Acquired
Last Round
Undisclosed
Team
1
1-10 employees
Confidence
76/100
News
2
articles
About
MitoCareX Bio is a drug discovery company focusing on the discovery and development of novel therapies for hard-to-treat lung cancer by targeting mitochondrial transporters (SLC25 protein family). To discover new potential drugs targeting human mitochondrial carriers, MitoCareX Bio has developed its MITOLINE algorithm and other advanced computational capabilities to generate reliable 3D models for its mitochondrial proteins of interest – a major key step for utilizing CADD. To recognize novel small molecule scaffolds interacting with their proteins of interest, it uses its advanced cloud-based computational platform to efficiently screen numerous small molecules against our 3D models. The selected hit candidates are then progressed along the pre-clinical path.
Classification
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Core Technology
BiologicalsMolecules
Target Customer
Healthcare & Life SciencesLife SciencesPharmaceuticals
Tags
pharmaceuticalscancercancer-therapyoncology
Funding & Events
Mar 2025
Exit Undisclosed
News (2)
Feb 26, 2025 · www.nasdaq.com
N2OFF, Inc. Enters Agreement to Acquire MitoCareX Bio Ltd. to Expand Cancer Therapeutics Portfolio
Jan 6, 2025 · www.globenewswire.com
growth-positive
SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results
Product StagePartners
Details
Product Stage
R&D
Employees
1-10
Exact Count
5
District
Center District
Founded
2022
Registrar
516570421
Locations
Tel Aviv-Yafo, Israel
Links
Website
LinkedIn
Admin
Last Update
Aug 5, 2025
Verified by
Yanina Wainscheinker
Missing
sector, business model, video or image, funding rounds, markets, not claimed
Team (1)
Alon Silberman
Founder & CSO
Founder
Internal
Created by
Yanina Wainscheinker (yanina.wainscheinker@sncentral.org)
Created
2025-03-25T00:00:00.000Z
Last editor
Matan Eblagon (matane@sncentral.org)
Status
Acquired by N2OFF on Mar, 2025